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John Reed said “Apoptosis is similar to a rheostat, whichbalances cellular survival and death signals” while provid-
ing an overview of the apoptosis at this meeting. Chemother-
apy, radiation therapy, inhibition, or withdrawal of tumor
growth factors can initiate the process of programmed cell
death. In normal cells, there is an appropriate balance be-
tween signals driving cell survival and those promoting cell
deaths. In neoplastic cells, survival signals frequently super-
sede death signals, resulting in resistance to a variety of
antineoplastic treatments. Although autophagy and necrosis
are also involved in cancer cell death, it is likely that tumor
cell death occurs predominantly through apoptosis. Initiation
of apoptosis occurs through intrinsic or extrinsic pathways
with each mechanism promoting conversion of procaspases
to caspases, proteolytic enzymes, which execute programmed
cell death.
Mitochondrial outer membrane permeability (MOMP)
plays a major role in initiation of the intrinsic apoptotic pathway.
Increasing MOMP results in release of mitochondrial cytro-
chrome C, which binds to apoptosis protein activating factor and
subsequently activates procaspases. MOMP is controlled by the
balance of Bcl-2 family proapoptotic and antiapoptotic proteins.
Bcl-2 and closely related proapoptotic proteins which in-
crease mitochondrial membrane permeability resulting in
increased cellular survival. Strategies for inhibiting BCL-2
activity include antisense oligonucleotides, small molecule
antagonists, and transcription regulators.
Antisense Bcl-2 oligonucleotides combined with che-
motherapy in treating chronic lymphocytic leukemia resulted
in a significantly higher response rate and longer response
duration. Adding a Bcl-2 antisense oligonucleotide to che-
motherapy did not improve outcome in a randomized small
cell lung cancer trial led by the Cancer and Leukemia Group
B. Identification of BH3 peptides, endogenous Bcl-2 in-
hibitors that bind to a cleft in Bcl-2, has provided another
strategy for enhancing apoptosis. Several molecules that
mimic the effect of the BH3 peptides are currently in
clinical development.
Cellular stress including hypoxia, glucose deprivation,
and pathogens induces unfolding of proteins in the endoplas-
mic recticulum (unfolding protein responses [UPR]). If the
unfolded proteins response is not reversed, both caspase
dependent and independent cell death can occur. In cancer,
there is overexpression of proteins which protect against cell
death triggered by UPR. Identification of these protective
proteins provides another potential group of targets, which
could be manipulated to enhance apoptosis in cancer cells.
The following presentations will describe clinical de-
velopment of death receptor agonists, a Bcl-2 inhibitor, and a
compound that inhibits survivin.
SUMMARY OF PRESENTATIONS
Apo2L/TRAIL
Recombinant human Apo2L/TRAIL is a soluble zinc-
coordinated homotrimeric protein, which closely resembles the
natural ligand and binds to death receptors 4 and 5, death
receptor decoys 1 and 2, and osteoprotegrin. Although Apo2L/
TRAIL initiates apoptosis in many types of cancer cell lines, it
does not promote apoptosis in normal cells. Single agent activity
has been observed in non-small cell lung cancer and colorectal
cancer xenografts, and synergy has been found with carboplatin
and paclitaxel in the H460 non-small cell lung cancer xenografts
model. Currently, phase I/II trials are being done in relapsed
follicular non-Hodgkin Lymphoma (combined with Rituxan), in
second-line colorectal cancer (combined with CPT-11 and cetux-
imab), and in previously untreated stage IV non-small cell lung
cancer (combined with carboplatin-paclitaxel-bevacizumab).
In a phase I study, Apo2L/TRAIL was tested on the
following schedule—8 mg/kg/d for 5 days every 21 days and
20 mg/kg/d for 2 days every 21 days. Each of these Apo2/
TRAIL schedules has been combined with paclitaxel 200
mg/m2, carboplatin area under the curve (AUC)  6, and
bevacizumab 15 mg/kg repeated every 21 days. Apo2/TRAIL
was well tolerated in combination with paclitaxel-carbopla-
tin  bevacizumab, and PK studies showed no effect of
Apo2L/TRAIL on the PK of carboplatin, paclitaxel, or bev-
acizumab. Currently, randomized phase II trials are testing
Apo2L/TRAIL in combination with carboplatin, paclitaxel,
and bevacizumab in eligible patients and with carboplatin and
paclitaxel in bevacizumab ineligible patients. Subsequent
development of Apo2/Trail in non-small cell lung cancer will
be determined by the results of these studies.
Mapatumumab—DR4 Agonist
DR4 (TRAIL_R1) is expressed in non-small cell lung
cancer, suggesting that it might be an important therapeutic
target in this tumor type. Mapatumumab, a human monoclo-
nal antibody that binds to DR4 (TRAIL-R1), has shown
single agent activity in non-small cell lung cancer xenografts.
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Potential determinants of single agent mapatumumab activity
include DR4 expression, decoy receptor expression, cFLIP
expression, receptor glycosylation, activity of the inhibitor of
apoptosis protein family proteins, and the activity of the
intrinsic apoptotic pathway. Currently, none of these molec-
ular parameters has been identified as a predictor of mapatu-
mumab effectiveness.
Mapatumumab given at a dose of 10 mg/kg every 3
weeks as a single agent showed no objective responses in
previously treated patients with non-small cell lung cancer.
Phase I trials showed that mapatumumab could be given at a
dose of 30 mg/kg with gemictabine and cisplatin and at a dose
of 20 mg/kg every 21 days with a standard paclitaxel—
carboplatin regimen. No PK interaction was observed with
carboplatin or paclitaxel. A randomized phase II trial com-
paring carboplatin paclitaxel alone to the same chemotherapy
regimen combined with mapatumumab at a dose of 10 mg/kg
or 30 mg every 21 days was completed in July 2008. Subse-
quent development of mapatumumab in non-small cell lung
cancer will depend on the results of this study.
Apomab—DR5 Agonist
One of the questions regarding DR5 agonist is whether
there are significant differences between the available pep-
tides. Apomab, a fully human IgG1 was escalated from 1 to
10 mg/kg in a phase I trial. Two dose-limiting toxicities were
observed at 10 mg/kg, one reversible grade 3 elevation of
transaminases and the other a clinically significant pulmonary
embolism. Minor responses were observed in colorectal can-
cer, ovarian cancer, and chondrosarcoma. A randomized phase
II trial comparing paclitaxel 200 mg/m2, carboplatin AUC  6,
and bevacizumab at a dose of 15 mg/kg every 3 weeks was
compared with the same regimen combined apomab 10 mg/kg
every 21 days. This trial has completed accrual.
AMG 655—TRAIL R2 Agonist
In a phase Ib trial, AMG 655 starting at dose of 5 mg/kg
every 21 days was combined with paclitaxel 200 mg/m2 and
carboplatin AUC of 6 every 21 days, currently paclitaxel—
carboplatin is being combined with AMG at a dose of 5
mg/kg or 10 mg/kg. These regimens are being compared with
the doublet regimen of paclitaxel and carboplatin in a ran-
domized phase II study. In addition, the Southwest Oncology
Group is planning a randomized phase II trial comparing
AMG 655 alone (15 mg/kg) to pemetrexed (500 mg/m2) plus
Amgen 655 (15 mg/kg). Each regimen is repeated every 3
weeks. Subsequent development of AMG 655 in non-small
cell lung cancer is pending the results of these randomized
phase II studies.
Bcl-2 Inhibitors: ABT-737 and ABT-263
Bcl-2 is expressed in the majority of small cell lung
cancers, and expression of this protein is associated with
therapeutic resistance, suggesting that Bcl-2 could be an
important target in small cell lung cancer. Preclinical studies
in both cell lines and in xenografts show that Bcl-2 inhibitors
are more effective in cells with high-expression Bcl-2,
whereas resistant cells have lower Bcl-2 expression. ABT-
737 showed single agent activity in small cell lung cancer
xenografts, and there was increased effect in combination
with etoposide.
ABT-263 is currently being tested in a phase I/II study.
Eligibility included small cell lung cancer and other solid
tumors. The initial schedule involved daily dosing on day 1 to
14 with cycles being repeated every 21 days. The initial dose
of 10 mg was escalated to 475 mg. In addition, a continuous
daily dosing is also being evaluated. Dose-dependent, tran-
sient thrombocytopenia related to ABT-263 induced apopto-
sis was observed, but it was not dose limiting.
ABT-263 was well tolerated up to a dose of 425 mg/d
for 14 consecutive days, repeated every 21 days. Minor
regressions were seen in a patient with previously treated
atypical carcinoid and in a patient with non-small cell lung
cancer. Subsequent development of ABT-263 will be based
on the pending results of the planned single agent trial in
previously treated patients and of the first-line phase II trial of
ABT-263 combined with etoposide and cesplatin.
YM155 (Survivin Suppressant)
Suvivin, a inhibitor of apoptosis protein family mem-
ber, is highly differentially expressed in cancer compared
with normal tissues. In a hormone refractory prostate cancer
cell lines, YM155 significantly reduced survivin expression.
YM155 produces tumor regression in diffuse large cell lym-
phoma xenografts. YM155 has been given as a continuous 7
day infusion every 3 weeks up to a dose 4.8 mg/m2 day with
dose-limiting toxicities being neutropenia and stomatitis. Par-
tial remissions were observed in three or five patients with
non-Hodgkin lymphoma and PSA responses occurred in two
of nine patients with hormone refractory prostate cancer in a
phase I trial. A minor response was also observed in a patient
with non-small cell lung cancer. Currently, YM155 combined
with a docetaxel is being tested in a variety of solid tumors in
a phase I/II study. Phase I/II studies of YM155 combined
with other cytotoxic agents are planned.
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